5-Amino-1MQ Overview for Researchers: Purity, Applications, and Scientific Background

5-Amino-1MQ Overview for Researchers: Purity, Applications, and Scientific Background
November 9, 2026
Reading Time: 8 mins
Science & Medicine NNMT Metabolism Research Guide
Research Guide

5-Amino-1MQ: What It Is, What Mouse Studies Showed, and Why There Is No Human Dose

Online it is sold as a "fat-burning peptide." It is neither a peptide nor a proven fat burner. Here is what the compound actually does, what the published research used, and where the evidence stops.

By Medical Team of Ordinary Peptides · Updated
Quick answer

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme NNMT, not a peptide. In obese mice, it reduced body weight by about 5% and white fat mass by about 35% in 11 days without changing food intake. In aged mice, it improved grip strength. No human clinical trial has been registered, so there is no validated human dose.

What 5-Amino-1MQ Actually Is, and What It Is Not

5-Amino-1MQ is 5-amino-1-methylquinolinium, usually supplied as the iodide salt (molecular weight about 286 g/mol). It selectively blocks nicotinamide N-methyltransferase (NNMT), an enzyme that attaches a methyl group to nicotinamide [1].

It is often called a "5-amino-1MQ peptide," but it is a small molecule with no amino-acid chain. It is structurally unrelated to peptides such as GHK-Cu or MOTS-c. Every reported effect so far comes from cell cultures and rodents.

How 5-Amino-1MQ Blocks NNMT and Shifts Metabolism

NNMT consumes two things cells need: nicotinamide, a building block for NAD+ (the central coenzyme of energy metabolism), and S-adenosylmethionine (SAM), the cell's main methyl donor. A 2014 study in Nature found NNMT is elevated in the fat tissue of obese mice, and that knocking it down protected mice from diet-induced obesity [2].

By inhibiting NNMT, 5-Amino-1MQ spares nicotinamide for NAD+ production and preserves SAM. In cultured fat cells it raised intracellular NAD+ by about 1.2 to 1.6 times and suppressed fat storage [1]. In mouse fat tissue, this appears to shift metabolism away from lipid accumulation. Whether the same happens in people is untested.

What the Studies Showed

Key published 5-Amino-1MQ / NNMT inhibitor studies
Study Model Main findings
Neelakantan et al., Biochem Pharmacol 2018 [1] Fat cells in culture; diet-induced obese mice, 11 days Mice lost ~5.1% body weight (controls gained ~1.4%). White fat mass fell ~35%, fat cell size more than 30%, total cholesterol ~30%. Food intake did not change. No observable adverse effects reported
Neelakantan et al., Biochem Pharmacol 2019 [3] Aged mice, muscle injury NNMT inhibition activated senescent muscle stem cells and improved regeneration of aged muscle
Dimet-Wiley et al., Sci Rep 2024 [4] Aged mice (22–24 months), 8 weeks, with or without exercise Grip strength ~40% higher with the inhibitor alone and ~20% with exercise alone vs sedentary controls. ~60% higher with both combined

These are well-designed experiments, but they are small, all in mice, and come largely from one research group. Several authors of the 2024 study were affiliated with a company developing NNMT inhibitors [4]. None of the outcomes has been confirmed in humans.

5-Amino-1MQ Dosage in Research

Many people search for a "5-amino-1MQ dosage." Here is what the published research actually used.

Concentrations and doses reported in published research
Setting Concentration / dose Result
Cultured fat cells [1] 1–60 µM NAD+ up 1.2–1.6 times
Fat cell differentiation [1] 30 µM and 60 µM Fat accumulation reduced by 50% and 70%
Diet-induced obese mice [1] 20 mg/kg, subcutaneous, three times daily, 11 days Weight and fat mass reduction, no change in food intake
Humans No dose established No registered clinical trials and no human pharmacokinetic data

Oral and subcutaneous "protocols" circulating online are usually built by converting the mouse dose with body-surface-area formulas. That math is a starting point for designing a clinical trial, not a validated dose. Human absorption, half-life and safe exposure have never been measured.

Research material: 5-Amino-1MQ · 5-Amino-1MQ capsules · 5-Amino-1MQ + NAD+ duo · Metabolic research compounds. For laboratory research use only.

Side Effects and Safety: What Is Known

No human safety studies exist. The main mouse study reported no observable adverse effects at the doses tested [1]. Online anecdotes mention digestive upset, nausea and fatigue, but no frequencies can be assigned to those reports.

If someone has already taken it

We do not endorse human use. Anyone with chest pain, difficulty breathing, fainting or other severe symptoms should seek emergency care immediately. For a non-urgent visit, a doctor will need context, so it helps to share:

  • the full name of the compound: 5-amino-1-methylquinolinium iodide;
  • that it is an NNMT inhibitor, not a peptide;
  • that only preclinical animal safety data exist;
  • the source, amount and any claimed purity, if known.
  • Not FDA-approved for obesity, aging or any other use.
  • Not a dietary supplement. It does not occur in the food supply, so it cannot qualify as a dietary ingredient.
  • No registered human trials. No Phase 1, 2 or 3 study appears on ClinicalTrials.gov.
  • Sold as a research chemical. Material is labeled for laboratory use. Purity claims (often ≥98% by HPLC) should be backed by a batch-specific certificate of analysis.

What the Internet Gets Wrong

  • "It's a peptide." It is a small-molecule quinolinium salt.
  • "It's proven to burn fat." Fat loss has been shown in mice over 11 days, not in people.
  • "Before-and-after photos prove it works." Photos cannot separate the compound's effect from diet, exercise and other substances used at the same time.
  • "Mouse doses converted to human doses are a protocol." Allometric conversion has never been tested for this compound in humans.
  • "It works like GLP-1 drugs." It does not reduce appetite. In mice, food intake stayed the same. For how appetite-based drugs differ, see the GLP-1 non-responder problem.

Bottom Line

5-Amino-1MQ is a selective NNMT inhibitor with a plausible metabolic mechanism and promising mouse data: less fat, better cholesterol and, in aged mice, stronger grip, especially combined with exercise. As of 2026 there are no human trials, no validated dose and no approved medical use. Any claim of proven human benefit is an extrapolation.

Frequently Asked Questions

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme NNMT. It is not a peptide. It is studied for effects on fat metabolism, NAD+ levels and muscle function in animals.

What dose of 5-Amino-1MQ was used in studies?

The key mouse study used 20 mg/kg injected subcutaneously three times daily for 11 days. Cell studies used 1–60 µM. These are research protocols, not human doses. No human dose has been established.

Does 5-Amino-1MQ work for weight loss?

In diet-induced obese mice, it reduced body weight by about 5% and white fat mass by about 35% in 11 days without lowering food intake. It has not been tested for weight loss in humans.

What are the side effects of 5-Amino-1MQ?

No human safety data exist. The main mouse study reported no observable adverse effects. Online reports of nausea, digestive upset and fatigue are anecdotal.

Is 5-Amino-1MQ legal or FDA-approved?

It is not FDA-approved for any use and is not a legal dietary supplement. It is sold as a research chemical for laboratory use.

Related Research

Research use only

This article summarizes published preclinical research for educational purposes and is not medical advice. Products offered on this site are for laboratory research use only and are not for human or veterinary consumption.

Sources

  1. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol, 2018. pubmed.ncbi.nlm.nih.gov/29155147
  2. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 2014;508:258–262.
  3. Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol, 2019;163:481–492.
  4. Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep, 2024;14:15554. pubmed.ncbi.nlm.nih.gov/38969654